Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lalonde

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Microbiology|June 15, 2007
Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispeciesMatthew S Lalonde, Ryan M Troyer, Aslam R Syed, et al.
Biochemical Society Transactions|January 26, 2005
Development and use of fluorescent nanosensors for metabolite imaging in living cellsM Fehr, S Okumoto, K Deuschle, et al.
Thrombosis Research|December 17, 2018
Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP studyD Projean, S Lalonde, J Morin, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2009
Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantageEsmeralda A Soares, André F Santos, Luis M Gonzalez, et al.
AIDS Research and Human Retroviruses|February 21, 2008
A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from UgandaRyan M Troyer, Matthew S Lalonde, Erika Fraundorf, et al.
Plos Pathogens|June 1, 2011
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNAMatthew S Lalonde, Michael A Lobritz, Annette Ratcliff, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2012
Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibilityAndré F A Santos, Denis M Tebit, Matthew S Lalonde, et al.
Chronic Stress (Thousand Oaks, Calif.)|October 1, 2021
Sex Differences in Peritraumatic Inflammatory Cytokines and Steroid Hormones Contribute to Prospective Risk for Nonremitting Posttraumatic Stress DisorderChloe S Lalonde, Yara Mekawi, Kelly F Ethun, et al.
The Oncologist|July 7, 2023
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the SoutheastChloe S Lalonde, Jeffrey M Switchenko, Madhusmita Behera, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Microbiology|June 15, 2007
Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispeciesMatthew S Lalonde, Ryan M Troyer, Aslam R Syed, et al.
Biochemical Society Transactions|January 26, 2005
Development and use of fluorescent nanosensors for metabolite imaging in living cellsM Fehr, S Okumoto, K Deuschle, et al.
Thrombosis Research|December 17, 2018
Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP studyD Projean, S Lalonde, J Morin, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2009
Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantageEsmeralda A Soares, André F Santos, Luis M Gonzalez, et al.
AIDS Research and Human Retroviruses|February 21, 2008
A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from UgandaRyan M Troyer, Matthew S Lalonde, Erika Fraundorf, et al.
Plos Pathogens|June 1, 2011
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNAMatthew S Lalonde, Michael A Lobritz, Annette Ratcliff, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2012
Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibilityAndré F A Santos, Denis M Tebit, Matthew S Lalonde, et al.
Chronic Stress (Thousand Oaks, Calif.)|October 1, 2021
Sex Differences in Peritraumatic Inflammatory Cytokines and Steroid Hormones Contribute to Prospective Risk for Nonremitting Posttraumatic Stress DisorderChloe S Lalonde, Yara Mekawi, Kelly F Ethun, et al.
The Oncologist|July 7, 2023
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the SoutheastChloe S Lalonde, Jeffrey M Switchenko, Madhusmita Behera, et al.
Pageof 3